Plain-English fact sheet
Thymosin alpha-1
Also known as Tα1, thymalfasin, Zadaxin
Thymosin alpha-1 has human research in hepatitis, sepsis, and immune modulation, but trial results are mixed and no U.S. product is FDA approved.
Quick answer
Thymosin alpha-1 is a 28-amino-acid immune-signaling peptide studied in infections, sepsis, liver disease, and cancer-support settings. It is not FDA approved to prevent or treat infection, 'boost immunity,' treat cancer, or for any other U.S. use.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Thymosin alpha-1?
Thymosin alpha-1 is a synthetic version of a peptide derived from prothymosin alpha and studied as an immune modulator.
It is distinct from thymosin beta-4 and from the TB-500 fragment; the shared 'thymosin' name does not make their biology or evidence interchangeable.
Why are people interested in it?
Trials have explored chronic hepatitis, sepsis, immune dysfunction, respiratory infections, and combinations with cancer treatment.
Broad 'immune boost' marketing flattens condition-specific and sometimes conflicting trial findings into a claim the evidence cannot support.
Current regulatory status
Thymosin alpha-1 has no FDA-approved product or indication. FDA has specifically stated that it is not approved to treat or prevent COVID-19 or any other condition and identifies compounded-product evidence and quality concerns.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Condition-specific immune modulation
- Adjunctive research in infections, liver disease, and cancer care
Evidence snapshot
Multiple human trials exist, including randomized studies in hepatitis and sepsis, but results vary by condition and design. The evidence does not support a general immune-enhancement claim or an FDA-approved U.S. use.
Potential benefits being researched
- Some trials and meta-analyses report signals in selected sepsis or hepatitis outcomes.
- Other randomized studies found no significant benefit on key clinical endpoints, so results cannot support a universal immune claim.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA identifies potential immune reactions, peptide impurities, active-ingredient characterization problems, and inadequate safety information for compounded products.
- Immune modulation can have condition-specific tradeoffs, especially in severe illness or alongside other treatments.
- Unapproved products introduce quality, purity, sterility, strength, and labeling uncertainty.
What we still do not know
- Which specific conditions and patient subgroups, if any, have a reproducible clinical benefit
- Long-term and uncommon harms
- How it compares with current standard treatments
- Whether findings from one formulation, country, or clinical setting transfer to another
Plain-English takeaway
Thymosin alpha-1 has more human research than many experimental peptides, but the evidence is condition-specific and mixed. It should not be described as a general immune booster or an FDA-approved U.S. therapy.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: safety risks for selected compounded bulk substances
FDA's current substance-specific summary of evidence gaps and potential safety risks.
- 2FDA annual report: unapproved thymosin alpha-1 claims
FDA statement that thymosin alpha-1 is not approved to treat or prevent COVID-19 or any other condition.
- 3ETASS randomized sepsis trial
Multicenter randomized study in severe sepsis with important setting and design limits.
- 4Phase 3 chronic hepatitis B trial
Randomized placebo-controlled trial whose primary response difference was not statistically significant.
- 5Randomized study in HBV-related cirrhosis
Large randomized study finding no significant difference in the composite clinical endpoint.